Novel strategies to improve DNA vaccine immunogenicity

Current Gene Therapy

Volumn 11, Issue 6, 2011, Pages 479-484

  Coban, Cevayir ^a   Kobiyama, Kouji ^a,b   Aoshi, Taiki ^a,b   Takeshita, Fumihiko ^a,b   Horii, Toshihiro ^c   Akira, Shizuo ^a   Ishii, Ken J ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Adjuvant; CPG motifs; DNA vaccine; Innate immunity; Sting; Tbk1; Tlr9; Type I interferon

Indexed keywords

DNA VACCINE; DOUBLE STRANDED DNA; INFLAMMASOME; INTERFERON; PLASMID DNA; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTATION; ARTICLE; CELL TYPE; HUMORAL IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; DENDRITIC CELLS; DNA; HUMANS; IMMUNITY, HUMORAL; INFLAMMASOMES; MEMBRANE PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; VACCINES, DNA;

EID: 82055176771     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311798192815     Document Type: Article

References (56)

1. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239: 62-84.
2. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005; 55: 25-40.
3. Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75: 4040-7.
4. Corbeil S, Lapatra SE, Anderson ED, et al. Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of infectious hematopoietic necrosis virus in rainbow trout oncorhynchus mykiss using DNA vaccines. Dis Aquat Organ 1999; 39: 29-36.
5. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284-90.
6. Kibuuka H, Kimutai R, Maboko L, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010; 201: 600-7.
7. Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA METRAP against malaria infection in Gambian adults. PLoS Med 2004; 1: e33.
8. Ishii KJ, Weiss WR, Ichino M, Verthelyi D, Klinman DM. Activity and safety of DNA plasmids encoding IL-4 and IFN gamma. Gene Ther 1999; 6: 237-44.
9. Applequist SE, Rollman E, Wareing MD, et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 2005; 175: 3882-91.
10. Stevenson FK. DNA vaccines and adjuvants. Immunol Rev 2004; 199: 5-8.
11. Sasaki S, Xin KQ, Okudela K, Okuda K, Ishii N. Immunomodulation by apoptosis-inducing caspases for an influenza DNA vaccine delivered by gene gun. Gene Ther 2002; 9: 828-31.
12. Sasaki S, Amara RR, Oran AE, Smith JM, Robinson HL. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 2001; 19: 543-7.
13. Moore AC, Hill AV. Progress in DNA-based heterologous primeboost immunization strategies for malaria. Immunol Rev 2004; 199: 126-43.
14. Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 2006; 6: 561-78.
15. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011.
16. Broderick KE, Shen X, Soderholm J, et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 2011; 18: 258-65.
17. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007; 6: 797-808.
18. Pokorna D, Rubio I, Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008; 6: 4.
19. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589: 1-13.
20. Ishii KJ, Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007; 27: 363-71.
21. Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008; 3: 352-63.
22. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
23. Barber GN. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 2011; 23: 10-20.
24. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-58.
25. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.
26. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
27. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-4.
28. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635-9.
29. Kojima Y, Xin KQ, Ooki T, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002; 20: 2857-65.
30. Pontarollo RA, Babiuk LA, Hecker R, Van Drunen Littel-Van Den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J Gen Virol 2002; 83: 2973-81.
31. Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J Leukoc Biol 2005; 78: 647-55.
32. Spies B, Hochrein H, Vabulas M, et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003; 171: 5908-12.
33. Babiuk S, Mookherjee N, Pontarollo R, et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 2004; 113: 114-20.
34. Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine 2007; 25: 6341-7.
35. Rottembourg D, Filippi CM, Bresson D, et al. Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. J Immunol 2010; 184: 7100-7.
36. Takeshita F, Tanaka T, Matsuda T, et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006; 80: 6218-24.
37. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002; 76: 6652-9.
38. Castaldello A, Sgarbanti M, Marsili G, et al. Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination. J Cell Physiol 2010; 224: 702-9.
39. Ishii KJ, Kawagoe T, Koyama S, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008; 451: 725-9.
40. Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7: 40-8.
41. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008; 4: 453-6.
42. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455: 674-8.
43. Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006; 127: 157-70.
44. Tsuchida T, Zou J, Saitoh T, et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 2010; 33: 765-76.
45. Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4: 491-6.
46. Sharma S, tenOever BR, Grandvaux N, et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003; 300: 1148-51.
47. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788-92.
48. Shirota H, Petrenko L, Hattori T, Klinman DM. Contribution of IRF-3 mediated IFNbeta production to DNA vaccine dependent cellular immune responses. Vaccine 2009; 27: 2144-9.
49. Roberts TL, Idris A, Dunn JA, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323: 1057-60.
50. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458: 509-13.
51. Burckstummer T, Baumann C, Bluml S, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10: 266-72.
52. Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458: 514-8.
53. Okuda K, Kawamoto S, Fukushima J. Cytokine and costimulatory factor-encoding plasmids as adjuvants for DNA vaccination. Methods Mol Med 2000; 29: 197-204.
54. Horii T, Shirai H, Jie L, et al. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int 2010; 59: 380-6.
55. Coban C, Igari Y, Yagi M, et al. Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 2010; 7: 50-61.
56. Coban C, Horii T, Akira S, Ishii KJ. TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine. Expert Rev Vaccines 2010; 9: 775-84.